GSK's Blujepa met primary endpoints in phase 3 trials, showing 58.5% success in EAGLE-3 vs. 43.6% for nitrofurantoin in uUTI treatment. The FDA approved Blujepa for uUTIs in female adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback